Possible macrophage activation in melanoma patients receiving combined kinase inhibitor therapy following anti-PD-1 therapy: a cytokine profiling study of two cases

Ann Oncol. 2017 Oct 1;28(10):2624-2625. doi: 10.1093/annonc/mdx325.

Authors

H Umemura¹, O Yamasaki², S Morizane², K Iwatsuki²

Affiliations

¹ Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Japan. Electronic address: ugn11252@nifty.com.
² Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Japan.

PMID: 28651362
DOI: 10.1093/annonc/mdx325

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cytokines / blood*
Cytokines / immunology
Female
Humans
Imidazoles / administration & dosage
Indoles / administration & dosage
Macrophage Activation / drug effects*
Macrophage Activation / immunology
Male
Melanoma / blood
Melanoma / drug therapy*
Melanoma / enzymology
Melanoma / immunology*
Middle Aged
Nivolumab
Oximes / administration & dosage
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / immunology
Protein Kinase Inhibitors
Pyridones / administration & dosage
Pyrimidinones / administration & dosage
Sulfonamides / administration & dosage
Vemurafenib

Substances

Antibodies, Monoclonal
Cytokines
Imidazoles
Indoles
Oximes
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Protein Kinase Inhibitors
Pyridones
Pyrimidinones
Sulfonamides
Vemurafenib
Nivolumab
trametinib
dabrafenib